Development of prototype to demonstrate the production options for the use of SofMat 3D technology in sequential marking within the pharmaceutical sector.

假冒产品给英国经济造成的损失估计为每年90亿英镑（国际商会商业犯罪服务参考CIB-9-0556 11-11-2009）。经济的所有领域都受到假冒商品的影响，从品牌服装到药品、汽车和航空航天零部件等关键商品。没有哪个行业能免受假冒产品的影响。这个问题在制药行业被认为是如此之大，以至于组织了一次年度会议（2013年5月召开的药品反假冒会议），致力于确保制药供应链的安全，以阻止假冒药品和设备的进入。人们还花了很多时间来使防伪药品的立法全球化，但迄今为止还没有根据世界卫生组织（www.who.int/impact）.The)的信息开发出简单的产品认证的使用点方法。SofMat项目将用于实施制药部门的建议，以开发与现有批处理并行使用的3D标记系统。该过程可用于顺序标记药物而不掺杂产品，确保FDA法规可以轻松遵守。这个过程在市场上是独一无二的，执行起来很简单，使用的是将在这个项目中开发的带有智能手机技术的阅读器。该产品首次将假冒产品的识别置于供应链中，而不是在生产商或政府机构手中。通过在整个供应链中轻松识别，这允许更广泛的识别和清除假冒商品。作为该制药项目的后续项目，公司将确定该技术是否可用于其他领域，例如：汽车和航空航天。这些下一个市场已经选择使用市场报告，确定这些作为下一个主要目标部门。

The cost to the UK economy of counterfeit products has been estimated at £9billion per year(ICC Commercial Crime Services Ref CIB-9-0556 11-11-2009). All areas of the economy areaffected by counterfeit goods, from branded clothing through critical goods such aspharmaceuticals and automotive & aerospace parts. No industry sector is immune from theeffects of counterfeit products. The problem is seen as so great in the pharmaceutical sectorthat an annual conference (Anti Counterfeiting for Pharmaceuticals, May 2013) has beenorganised, devoted to securing the pharmaceutical supply chain to stop entry of counterfeitdrugs & devices. Much time has also been devoted to globalise the legislation dealing withanti-counterfeit pharmaceutical products but no simple point of use method of productauthentification has been developed so far according to information from the World HealthOrganisation (www.who.int/impact).The SofMat project will be used to implement pharmaceutical sector suggestions to develop asequential 3D marking system that will be used side by side with the existing batch process.The process can be used to sequentially mark drugs without adulterating the product ensuringthat FDA legislations can be easily complied with. The process is unique in the marketplace& simple in execution, using a reader with smartphone technology which will be developedduring this project. This product for the first time places the identification of counterfeitgoods within the supply chain rather than in the hands of the producers or governmentalagencies. This allows a wider scope for identification & removal of counterfeit goods byallowing easy identification throughout the supply chain.As a follow up to this Pharmaceutical project the Company will determine whether thetechnology can be utilised in other sectors, eg: automotive & aerospace. These next marketshave been selected using a market report that identified these as the next prime target sectors.